A recent survey of 14 Wall Street analysts shows the average price target for West Pharmaceutical Services sits 26.42% above current levels, indicating strong bullish sentiment on the stock. Over the past three months, consensus earnings‐per‐share estimates for fiscal years 2025 and 2026 have been revised upward by an average of 4.8%, driven by improving mix in high-margin components and cost‐control initiatives. Analysts point to accelerating demand in parenteral drug delivery devices and the company’s ability to pass through higher raw-material costs as key drivers of the positive revision trend.

During its presentation at the 44th Annual J.P. Morgan Healthcare Conference, West’s management team reaffirmed full-year revenue growth guidance of 8% to 10%, underpinned by expanded capacity in North America and Europe. The company disclosed that capital expenditures of $240 million in fiscal 2025 will target two new automated syringe assembly lines and a dedicated fill-finish expansion in the Philippines. West also noted gross margin expansion of 140 basis points year-over-year, attributing the gain to operational efficiencies in its primary packaging segment.

West Pharmaceutical Services has agreed to sell a device manufacturing facility and associated intellectual property in Tempe, Arizona to AbbVie for $175 million, with closing expected in mid-2026. The transaction includes transfer of multiple production lines and proprietary 3.5 mL on-body injector technology, supporting both current immunology and next-generation neuroscience therapies. AbbVie intends to invest an additional $50 million to modernize the site and will absorb approximately 200 existing West employees, improving utilization rates at the plant and unlocking incremental free cash flow for West upon closure.